Health Canada authorizes Moderna's mRNA flu and flu-COVID vaccines
On Nov. 5, 2026 Moderna said Health Canada authorized mFLUSIVA (mRNA-1010) and mCOFLU (mRNA-1083) for adults 50 and older, making Canada the first country to authorize both. Moderna reported relative vaccine efficacy of 26.6 percent versus a standard-dose flu shot in adults 50 and older, and it gave no Canadian supply date. The Canadian Press reported that Moderna said the vaccines will not reach pharmacies this respiratory season.
/ Sources
/ About this story
Compiled by Venture Atlas from the sources above, using automated AI-assisted research. This is a summary of reporting published elsewhere, not original reporting - follow the source links for the full account. See our editorial standards.
Something wrong here? Email apostructura@gmail.com and we will fix it.
/ Related
- WHO advisers recommend Moderna's Bundibugyo shot for trialThursday, November 5, 2026
- UK MHRA authorizes Moderna XFG Spikevax updateMonday, September 7, 2026
- Moderna prices upsized $2.6 billion convertible notesTuesday, September 1, 2026
- FDA approves Moderna's updated 2026-2027 COVID vaccinesFriday, August 28, 2026